Literature DB >> 23572328

Pharmacologic treatment of sex offenders with paraphilic disorder.

Frederico Duarte Garcia1, Heloise Garcia Delavenne, Alessandra de Fátima Almeida Assumpção, Florence Thibaut.   

Abstract

Sexual offending is both a social and a public health issue. Evidence demonstrates that a combination of pharmacological and psychotherapeutic approaches may reduce or even eliminate deviant sexual behavior in sex offenders with paraphilic disorders. In this article, we will review pharmacological treatment options for sex offenders with paraphilias. Both serotonin selective reuptake inhibitors (SSRIs) and antiandrogen treatments have been used with reported success in decreasing recidivism. SSRIs have been used in mild types of paraphilias and juvenile paraphilias. Antiandrogen treatments seem to be effective in severe sex offenders with paraphilic disorders in order to reduce victimization. Combined pharmacological and psychotherapeutic treatment is associated with better efficacy. Imaging studies may improve the knowledge of paraphilic disorders and the mechanisms of action of current treatments. In spite of existing evidence, there is a need for independent, large-scale and good quality studies assessing the long-term efficacy and tolerance of treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572328     DOI: 10.1007/s11920-013-0356-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  40 in total

1.  The neurobiology of sexual function.

Authors:  C M Meston; P F Frohlich
Journal:  Arch Gen Psychiatry       Date:  2000-11

2.  Rehabilitation of child molesters: a cost-benefit analysis.

Authors:  R Prentky; A W Burgess
Journal:  Am J Orthopsychiatry       Date:  1990-01

Review 3.  Paedophilia: a review of the evidence.

Authors:  N McConaghy
Journal:  Aust N Z J Psychiatry       Date:  1998-04       Impact factor: 5.744

4.  Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia.

Authors:  M Maes; D van West; N De Vos; H Westenberg; F Van Hunsel; D Hendriks; P Cosyns; S Scharpé
Journal:  Neuropsychopharmacology       Date:  2001-01       Impact factor: 7.853

Review 5.  Current concepts in the pharmacotherapy of paraphilias.

Authors:  Frederico D Garcia; Florence Thibaut
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 6.  Psychological profile of pedophiles and child molesters.

Authors:  J B Murray
Journal:  J Psychol       Date:  2000-03

Review 7.  Human rights and the treatment of sex offenders.

Authors:  Tony Ward; Theresa A Gannon; Astrid Birgden
Journal:  Sex Abuse       Date:  2007-08-28

Review 8.  Testosterone and its metabolites modulate 5HT1A and 5HT1B agonist effects on intermale aggression.

Authors:  N G Simon; A Cologer-Clifford; S F Lu; S E McKenna; S Hu
Journal:  Neurosci Biobehav Rev       Date:  1998       Impact factor: 8.989

9.  Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment?

Authors:  F Thibaut; B Cordier; J M Kuhn
Journal:  Psychoneuroendocrinology       Date:  1996-05       Impact factor: 4.905

Review 10.  Drug treatment of paraphilic and nonparaphilic sexual disorders.

Authors:  David R P Guay
Journal:  Clin Ther       Date:  2009-01       Impact factor: 3.393

View more
  2 in total

Review 1.  The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the treatment of adolescent sexual offenders with paraphilic disorders.

Authors:  Florence Thibaut; John M W Bradford; Peer Briken; Flora De La Barra; Frank Häßler; Paul Cosyns
Journal:  World J Biol Psychiatry       Date:  2015-11-23       Impact factor: 4.132

Review 2.  The Biological Treatment of Paraphilic Disorders: an Updated Review.

Authors:  Brian J Holoyda; Denise C Kellaher
Journal:  Curr Psychiatry Rep       Date:  2016-02       Impact factor: 5.285

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.